Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis.

Authors :: Momotow, Jesko
Bühnen, Ina
Trautmann‐Grill, Karolin
Kobbe, Guido
Hahn, Dennis
Schroers, Roland
Heinrich, Bernhard
Gaska, Tobias
Forstbauer, Helmut
Schmidt, Burkhard
Boger, Regina
Hüttmann, Andreas
Heil, Gerhard
Kraemer, Doris M.
Krüger, William
Zeremski, Vanja
Grobe, Norbert
Jentsch‐Ullrich, Kathleen
Griesinger, Frank
Fuchs, Michael
Source :: British Journal of Haematology. Jul2022, Vol. 198 Issue 2, p401-404. 4p.
Publication Year :: 2022
Abstract: Overall, 33 patients (52%) continued treatment beyond investigator assessed PD and a total of 16 patients received additional concomitant radiotherapy and/or chemotherapy. The majority of patients experiencing PD during or after anti-PD1 treatment received additional therapies (21/37, 57%). Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. [Extracted from the article]

Full Text Access

Tools